Adverse reproductive outcomes such as recurrent miscarriage and repeated implantation failure are particularly stressful episodes for couples and challenging situations for physicians to manage. A growing area of interest, with increasing amounts of supporting evidence, is the use of intravenous immunoglobulin (IVIg) for the treatment of complex cases. IVIg is generally safe and well tolerated in pregnancy, even at high doses.19 Reassuring data have shown that IVIg treatment did not increase the rate of obstetric complications or lead to foetal teratogenicity. SummaryThere is a growing body of evidence that IVIg treatment can help patients with immune-mediated RPL or repeated implantation failure. IVIg treatment should be given pre-implantation, as this is more successful than administration post conception.

Source: Irish Independent November 07, 2024 09:13 UTC